Seeking Alpha

Alnylam Pharmaceuticals (ALNY) now surging 37% on heavy volume following positive Phase I trial...

Alnylam Pharmaceuticals (ALNY) now surging 37% on heavy volume following positive Phase I trial results for ALN-TTR02, a treatment for a genetic mutation of the transthyretin gene. The mutation causes a hereditary, systemic disease called ATTR, which can damage body organs and tissue such as the peripheral nerves and heart.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|